ctDNA-guided adjuvant chemotherapy for colorectal cancer-ready for prime time?

Claus L Andersen; Ellen Heitzer

doi:10.1016/j.ccell.2022.08.017

ctDNA-guided adjuvant chemotherapy for colorectal cancer-ready for prime time?

Cancer Cell. 2022 Sep 12;40(9):911-913. doi: 10.1016/j.ccell.2022.08.017. Epub 2022 Sep 1.

Authors

Claus L Andersen¹, Ellen Heitzer²

Affiliations

¹ Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
² Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria; Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Austria. Electronic address: ellen.heitzer@medunigraz.at.

PMID: 36055230
DOI: 10.1016/j.ccell.2022.08.017

Abstract

In stage II colorectal cancer, adjuvant chemotherapy is controversial, and overtreatment is substantial due to suboptimal risk stratification. In a recent New England Journal of Medicine article reporting from a prospective randomized phase II trial, Tie and colleagues demonstrate how ctDNA-guided risk-stratification reduces the use of adjuvant chemotherapy without compromising recurrence risk.

Publication types

Clinical Trial, Phase II
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Chemotherapy, Adjuvant
Circulating Tumor DNA* / genetics
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / genetics
Colorectal Neoplasms* / pathology
Humans
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / genetics
Neoplasm Recurrence, Local / pathology
Neoplasm Staging
Prospective Studies

Substances

Circulating Tumor DNA